Lee's Pharm to Start China Trials of In-licensed PD-L1 Candidate

A subsidiary of Lee's Pharm received permission to begin China clinical trials of ZKAB001, a PD-L1 immuno-oncology monoclonal antibody. Lee's Pharm, a Hong Kong company, in-licensed greater China rights to the candidate from San Diego's Sorrento Therapeutics in 2014 in a deal that could be worth up to $50 million. Lee's Pharm was granted approval to test ZKAB001 in three cancer indications. Its subsidiary, China Oncology Focus, is in charge of developing the drug. More details.... Stock Symbols: (HK: 0950) (NSDQ: SRNE) Share this with colleagues: // //